135 related articles for article (PubMed ID: 10855624)
1. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
Torizuka T; Zasadny KR; Kison PV; Rommelfanger SG; Kaminski MS; Wahl RL
J Nucl Med; 2000 Jun; 41(6):999-1005. PubMed ID: 10855624
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy.
Jacene HA; Filice R; Kasecamp W; Wahl RL
J Nucl Med; 2009 Jan; 50(1):8-17. PubMed ID: 19091903
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
[TBL] [Abstract][Full Text] [Related]
4. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ
Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618
[TBL] [Abstract][Full Text] [Related]
5. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
6. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.
Cazaentre T; Morschhauser F; Vermandel M; Betrouni N; Prangère T; Steinling M; Huglo D
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):494-504. PubMed ID: 19820933
[TBL] [Abstract][Full Text] [Related]
7. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L
Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155
[TBL] [Abstract][Full Text] [Related]
8. Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma.
Grgic A; Nestle U; Scheidhauer K; Puskas C; Ballek E; Hohloch K; Schubert J; König J; Pinkert J; Truemper L; Hellwig D; Kirsch CM
Nuklearmedizin; 2011; 50(1):39-47. PubMed ID: 21057722
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pretreatment ¹⁸F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ¹³¹I-rituximab.
Lim I; Park JY; Kang HJ; Hwang JP; Lee SS; Kim KM; Choi TH; Yang SH; Kim BI; Choi CW; Lim SM
Acta Haematol; 2013; 130(2):74-82. PubMed ID: 23548464
[TBL] [Abstract][Full Text] [Related]
10. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
DeNardo GL; Kukis DL; Shen S; DeNardo DA; Meares CF; DeNardo SJ
Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
McQuillan AD; Macdonald WB; Turner JH
Leuk Lymphoma; 2015 May; 56(5):1271-7. PubMed ID: 25065701
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of
Lee I; Byun BH; Lim I; Kim BI; Choi CW; Kim KM; Shin DY; Kang HJ; Lim SM
Ann Nucl Med; 2019 Dec; 33(12):881-890. PubMed ID: 31571043
[TBL] [Abstract][Full Text] [Related]
14. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.
Gates VL; Carey JE; Siegel JA; Kaminski MS; Wahl RL
J Nucl Med; 1998 Jul; 39(7):1230-6. PubMed ID: 9669400
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
Römer W; Hanauske AR; Ziegler S; Thödtmann R; Weber W; Fuchs C; Enne W; Herz M; Nerl C; Garbrecht M; Schwaiger M
Blood; 1998 Jun; 91(12):4464-71. PubMed ID: 9616140
[TBL] [Abstract][Full Text] [Related]
17. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
20. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.
Boucek JA; Turner JH
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]